Lupin launches Fosaprepitant for Injection

Pharma major Lupin Limited (Lupin) announced the launch of Fosaprepitant for Injection, 150 mg Single-Dose Vial, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Fosaprepitant for Injection, 150 mg Single-Dose Vial, is the generic equivalent of Emend® for Injection, 150 mg Single-Dose Vial, of Merck Sharp & Dohme Corp. (Merck), indicated for adults in combination with other antiemetic agents, for the prevention of:

- Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.

- Delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Fosaprepitant for Injection, 150 mg Single-Dose Vial, (RLD: Emend®) had annual sales of approximately USD 136 million in the U.S. (IQVIA MAT July 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.997.8 as compared to the previous close of Rs. 979.55. The total number of shares traded during the day was 94280 in over 3586 trades.

The stock hit an intraday high of Rs. 1022.35 and intraday low of 978.75. The net turnover during the day was Rs. 94476212.

Source : Equity Bulls

Keywords